These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9694740)

  • 41. Bone marrow aplasia after pipobroman: an immune-mediated mechanism?
    Triffet A; Straetmans N; Ferrant A
    Br J Haematol; 2001 Dec; 115(3):713-4. PubMed ID: 11736962
    [No Abstract]   [Full Text] [Related]  

  • 42. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
    Furgerson JL; Vukelja SJ; Baker WJ; O'Rourke TJ
    Am J Hematol; 1996 Feb; 51(2):137-40. PubMed ID: 8579054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of patients with essential thrombocythemia: current concepts and perspectives.
    Briere J; Guilmin F
    Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
    Higuchi T; Okada S; Mori H; Niikura H; Omine M; Terada H
    Cancer; 1995 Jan; 75(2):471-7. PubMed ID: 7812918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
    Boivin P
    Nouv Rev Fr Hematol (1978); 1993; 35(5):491-8. PubMed ID: 8295823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A fertile XY/XX chimeric male with chronic myeloid leukemia in a minor 46,XX cell line and a history of polycythemia vera and trisomy 9 in the major 46,XY cell line.
    Reddy KS; Schwartz GE; Jamedhor M
    Leuk Lymphoma; 2009 Aug; 50(8):1375-80. PubMed ID: 19562617
    [No Abstract]   [Full Text] [Related]  

  • 48. Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
    Mavrogianni D; Viniou N; Michali E; Terpos E; Meletis J; Vaiopoulos G; Madzourani M; Pangalis G; Yataganas X; Loukopoulos D
    Int J Hematol; 2002 May; 75(4):394-400. PubMed ID: 12041671
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman.
    Messora C; Bensi L; Vanzanelli P; Temperani P; Carotenuto M; Sacchi S
    Haematologica; 1996; 81(1):51-3. PubMed ID: 8900853
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
    LeBrun DP; Pinkerton PH; Sheridan BL; Chen-Lai J; Dubé ID; Poldre PA
    Cancer Genet Cytogenet; 1991 Jul; 54(1):21-5. PubMed ID: 2065312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.
    Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F
    Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of the myeloproliferative disorders with 32P.
    Berlin NI
    Eur J Haematol; 2000 Jul; 65(1):1-7. PubMed ID: 10914933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Maloisel F; Uettwiller F; Laplace A; Lioure B; Herbrecht R; Mark M; Dufour P
    Cancer Genet Cytogenet; 1999 Sep; 113(2):172-6. PubMed ID: 10484986
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute biphenotypic leukemia arising in a patient with essential thrombocythemia.
    Wong GC; Lee LH
    Am J Hematol; 2006 Aug; 81(8):624-6. PubMed ID: 16823822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia.
    Wahlin A; Golovleva I
    Eur J Haematol; 2003 Apr; 70(4):240-1. PubMed ID: 12656748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases.
    Merlat A; Lai JL; Sterkers Y; Demory JL; Bauters F; Preudhomme C; Fenaux P
    Leukemia; 1999 Feb; 13(2):250-7. PubMed ID: 10025899
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms.
    Trifa AP; Popp RA; Cucuianu A; Coadă CA; Urian LG; Militaru MS; Bănescu C; Dima D; Farcaş MF; Crişan TO; Petrov L; Gug C; Pop IV
    Leuk Lymphoma; 2012 Dec; 53(12):2496-7. PubMed ID: 22339435
    [No Abstract]   [Full Text] [Related]  

  • 59. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
    Passamonti F; Cazzola M
    Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
    [No Abstract]   [Full Text] [Related]  

  • 60. Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.
    Mizutani S; Kuroda J; Shimizu D; Horiike S; Taniwaki M
    Int J Hematol; 2010 Apr; 91(3):516-21. PubMed ID: 20146031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.